Navigation Links
FDA Approves Edarbi to Treat High Blood Pressure
Date:2/25/2011

SILVER SPRING, Md., Feb. 25, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Edarbi tablets (azilsartan medoxomil) to treat high blood pressure (hypertension) in adults.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Data from clinical studies showed Edarbi to be more effective in lowering 24-hour blood pressure compared with two other FDA-approved hypertension drugs, Diovan (valsartan) and Benicar (olmesartan).

"High blood pressure is often called the 'silent killer' because it usually has no symptoms until it causes damage to the body," said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Drug Products in the FDA's Center for Drug Evaluation and Research. "High blood pressure remains inadequately controlled in many people diagnosed with the condition, so having a variety of treatment options is important."

Edarbi will be available in 80 milligram and 40 mg doses, with the recommended dose set at 80 mg once daily. The 40 mg dose will be available for patients who are treated with high-dose diuretics taken to reduce salt in the body.

Blood pressure is the force of blood pushing against the walls of the arteries as the heart pumps. If blood pressure rises and stays high over time, it can damage the body in many ways. Nearly 1 in 3 adults in the United States has high blood pressure, which increases the risks of stroke, heart failure, heart attack, kidney failure, and death. 

Edarbi is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.

Adverse reactions reported by patients taking Edarbi in clinical trials were similar to those reported by those taking an inactive drug (placebo).

Edarbi has a boxed warning that says the use of the drug should be avoided in pr
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension
2. FDA Approves Product to Prevent Bleeding in People With Rare Genetic Defect
3. FDA Approves First 3-D Mammography Imaging System
4. FDA Approves 1st Pacemaker Designed to Work Safely During Some MRI Exams
5. FDA Approves Hologics Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
6. FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
7. FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
8. FDA Approves Viibryd to Treat Major Depressive Disorder
9. FDA Approves Head Lice Treatment for Children and Adults
10. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
11. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... NEW YORK , March 4, 2015 /PRNewswire/ ... orthopedic device market is the increasing elderly population, ... in a recent report from the healthcare market ... aging population coupled with other risk factors such ... orthopedic incidence worldwide. Demand for innovative product designs ...
(Date:3/4/2015)... March 4, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... the t:slim® and t:flex™ Insulin Pumps, today announced the closing ... of common stock at a price to the public of ... the underwriters of their option to purchase up to an ... were offered by Tandem. BofA Merrill Lynch ...
(Date:3/4/2015)... March 4, 2015 Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that Pedro ... The Opening Bell ® of the New York ... began trading as an NYSE MKT listed company on ... Exchange is a trusted partner to Asterias Biotherapeutics, and ...
Breaking Medicine Technology:Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3Tandem Diabetes Care Announces Closing of Underwritten Public Offering of Common Stock 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
... 2011 A free white paper that guides manufacturers ... processes is available from Microtest Laboratories. It is available ... many medical devices are made of high-tech materials such ... the use of various agents to aid in the ...
... CHICAGO and SAN DIEGO, June 6, 2011 ... TG01) in combination with erlotinib demonstrated significant and ... clinically relevant subset of biomarker-selected patients with non-small ... a platinum-containing regimen for advanced disease. Complete data ...
Cached Medicine Technology:New White Paper Helps Medical Device Manufacturers Validate Cleaning Processes 2Apricoxib Prolongs Time-to-Progression and Overall Survival in Biomarker-Selected NSCLC Patients 2Apricoxib Prolongs Time-to-Progression and Overall Survival in Biomarker-Selected NSCLC Patients 3Apricoxib Prolongs Time-to-Progression and Overall Survival in Biomarker-Selected NSCLC Patients 4
(Date:3/5/2015)... 05, 2015 In recognition of its ... patients, Soho Flordis International (SFI) has been honored by ... a global natural medicine company committed to identifying and ... quality, safety, and effectiveness. For these efforts the non-profit ... Commercial Investment in Phytomedicinal Research Award. , Phytomedicinal ...
(Date:3/5/2015)... 05, 2015 The Shaolin Chan Foundation ... and Wellness at Atlanta Shaolin Institute along with Grandmaster ... Industrial BLVD, Suite 500A, city of Peachtree Corners, Georgia. ... which is a non-profit organization that promotes natural, healthy ... medicine. , The seminar was well received by ...
(Date:3/4/2015)... 05, 2015 Understanding China’s New Medical ... p.m. – 3:00 p.m. EDT, http://www.fdanews.com/UnderstandingChinaMDRegs , ... regulations for medical devices in China. , These ... — research and development, approval, manufacturing, distribution, and post-market ... currently in development as well as those that are ...
(Date:3/4/2015)... The Asia-Pacific phthalic anhydride market is estimated to ... at a CAGR of 5.9% during the forecast ... the TOC of Asia-Pacific Phthalic Anhydride Market for ... the help of various tables and figures., ... derivative of phthalic acid, which is either obtained ...
(Date:3/4/2015)... 04, 2015 The federal litigation established ... statin drug caused patients to develop Type 2 diabetes ... District of South Carolina. According to court documents, the ... 26, 2015 at 10:00 a.m. In advance of the ... Joint Status report to the Court by March 19, ...
Breaking Medicine News(10 mins):Health News:SFI Receives Prestigious ABC’s Tyler Award Given For Global Research Effort 2Health News:SFI Receives Prestigious ABC’s Tyler Award Given For Global Research Effort 3Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 2Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 3Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 2Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 3Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3
... OFFER CCHIT MANDATED FEATURESLOS ANGELES, April 20 ... Board: FVRL), which through its wholly-owned operating ... Personal Health Records ("PHRs") ( www.mymedicalrecords.com ... storage solutions ( www.myesafedepositbox.com ), ...
... Medarex, Inc. (Nasdaq: MEDX ) today ... trial of MDX-1401 in patients with relapsed or refractory ... activity signals. MDX-1401 is a fully human, non-fucosylated ... that is present on malignant cells of HL as ...
... 20 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, ... the three-month period ended March 31, 2009. First ... compared to $1.173 million for the same period ... any quarter in the Company,s history and, as ...
... Mix Featuring Arthur and Friends , BURLINGTON, Mass. ... Cherrybrook Kitchen, the brand known for allergy-friendly desserts and ... Arthur, the award-winning PBS character whose TV show entertains ... challenges, lessons and obstacles of growing up. Launched in ...
... The Leukemia & Lymphoma SocietyWHITE PLAINS, N.Y., April 20 ... mothers perform on behalf of their children and other loved ... something special to pay tribute to mothers.Consider the heroic gesture ... nothing more terrifying for a mother than to watch helplessly ...
... today by Dystonia Medical Research Foundation: WHAT: ... the Dystonia , Medical Research Foundation (DMRF) -- ... for Dystonia (a "poker run" primarily for motorcyclists), a fundraiser ... this rare, but disabling, neurological disorder.In 2005, Debbi Mack published ...
Cached Medicine News:Health News:MMR Information Systems, Inc. Announces 250,000 Membership Milestone and Granting of International Patents 2Health News:MMR Information Systems, Inc. Announces 250,000 Membership Milestone and Granting of International Patents 3Health News:MMR Information Systems, Inc. Announces 250,000 Membership Milestone and Granting of International Patents 4Health News:MMR Information Systems, Inc. Announces 250,000 Membership Milestone and Granting of International Patents 5Health News:Medarex Announces Clinical Data for MDX-1401 in Hodgkin's Lymphoma at Annual Meeting of the American Association for Cancer Research 2Health News:Medarex Announces Clinical Data for MDX-1401 in Hodgkin's Lymphoma at Annual Meeting of the American Association for Cancer Research 3Health News:Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter 2Health News:Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter 3Health News:Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter 4Health News:Cherrybrook Kitchen Announces New Partnership With Arthur 2Health News:Cherrybrook Kitchen Announces New Partnership With Arthur 3Health News:This Mother's Day Celebrate a Mother's Love 2Health News:Maryland Mystery Author Organizes Fundraising Ride for Rare Neurological Disorder 2
... 2000 is designed to monitor, store and measure ... (stress-testing). The system can organize the amount of ... for a quick review and printout of an ... is transmitted via a small portable ECG recorder ...
... Burdick ExTOL systems feature your choice ... multi-channel electrocardiographs, an easy-to-operate monitor and ... ExTOL exercise stress testing systems also ... measurement point, pre-programmed or custom protocols, ...
... w/ Remote/Controller. Includes Full Range ... Children. Multiple 20/20 slides. Polarized ... allows you to customize your slide choices. ... with Long Life. Variety of mounting options. ...
... The Ultimate in ... Octopus 4.3 stabilizer features ... unmatched stability in the ... 4.3 Stabilizer features the ...
Medicine Products: